{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/CNA108223","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00435838","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[],"assignment":"","brief_summary":"This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B*5701 can reduce the incidence of hypersensitivity reactions to abacavir). This study aims to collect data on approximately 35 subjects who withdrew from CNA106030 when found to be HLA-B*5701 positive. HIV disease management and adverse event data in these subjects, where the risk/benefit ratio of treatment with abacavir may alter subsequent prescribing, will be collected","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Study of Patient Management in HIV-1 Infected Patients Found to have the Genetic Marker HLA-B*5701","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV Infection","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 18:02:12","criteria":"Inclusion Criteria: - Subjects who have received notification not to receive abacavir in the CNA106030 study because of a positive HLA-B*5701 screen result, and were subsequently withdrawn from protocol CNA106030. - Subjects willing and able to understand and provide written informed consent prior to participation in this study. - French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. Exclusion criteria: - Subjects who were not enrolled in the CNA106030 study - Subjects who are not HLA-B*5701 positive - Subjects who do not consent to being told their HLA-B*5701 status","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"","display_phase_internal":"","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"35","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"no","id":"b499b036-0ddc-5d71-be52-7e1fa0a26ac2","internal":{"content":null,"contentDigest":"0f639fbf864e49d8096149af7b7aa3c8","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Subjects who have received notification not to receive abacavir in the CNA106030 study because of a positive HLA-B*5701 screen result, and were subsequently withdrawn from protocol CNA106030. - Subjects willing and able to understand and provide written informed consent prior to participation in this study. - French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. Exclusion criteria: - Subjects who were not enrolled in the CNA106030 study - Subjects who are not HLA-B*5701 positive - Subjects who do not consent to being told their HLA-B*5701 status","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"No Intervention -- Observational study","intervention_type":"Drug"}],"interventional_subtype":"","is_fda_regulated":null,"is_high_value":false,"is_ind_study":false,"keywords":["HLa-B*5701 Abacavir"],"last_follow_up_date":null,"links":[],"locations":[{"City":"Vienna","Latitude":"48.2210429","CountryDisplay":"Austria","Longitude":"16.2277052","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"A-1140","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Vienna","Latitude":"48.2248956","CountryDisplay":"Austria","Longitude":"16.356965","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"A-1090","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Salzburg","Latitude":"47.8051393","CountryDisplay":"Austria","Longitude":"13.0380686","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"A-5020","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Innsbruck","Latitude":"47.269258","CountryDisplay":"Austria","Longitude":"11.4040792","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"A-6020","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"La Chaux-de-Fonds","Latitude":"47.1034892","CountryDisplay":"Switzerland","Longitude":"6.8327838","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"CH 2301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bruxelles","Latitude":"50.8427501","CountryDisplay":"Belgium","Longitude":"4.3515499","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Brussels","Latitude":"50.8238652","CountryDisplay":"Belgium","Longitude":"4.2986584","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1070","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Barcelona","Latitude":"41.3494786","CountryDisplay":"Spain","Longitude":"2.1033017","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08907","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.3672276","CountryDisplay":"Spain","Longitude":"-3.6978264","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28041","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Badalona","Latitude":"41.474766","CountryDisplay":"Spain","Longitude":"2.2285864","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08916","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Alicante","Latitude":"38.3616509","CountryDisplay":"Spain","Longitude":"-0.489172","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"03010","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Valencia","Latitude":"39.4798873","CountryDisplay":"Spain","Longitude":"-0.3979657","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"46015","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Alcala de Henares","Latitude":"40.5108369","CountryDisplay":"Spain","Longitude":"-3.3237824","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28805","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Malaga","Latitude":"36.7978204","CountryDisplay":"Spain","Longitude":"-5.1353887","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"29020","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Padova","Latitude":"45.397898","CountryDisplay":"Italy","Longitude":"11.9046617","Name":"GSK Investigational Site","StateDisplay":"Veneto","PostalCode":"35128","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Milano","Latitude":"45.4174623","CountryDisplay":"Italy","Longitude":"9.1627615","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20142","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Roma","Latitude":"41.8977003","CountryDisplay":"Italy","Longitude":"12.5097274","Name":"GSK Investigational Site","StateDisplay":"Lazio","PostalCode":"00185","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bolzano","Latitude":"46.4982953","CountryDisplay":"Italy","Longitude":"11.3547582","Name":"GSK Investigational Site","StateDisplay":"Trentino-Alto Adige","PostalCode":"39100","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Rimini","Latitude":"44.0678288","CountryDisplay":"Italy","Longitude":"12.5695158","Name":"GSK Investigational Site","StateDisplay":"Emilia-Romagna","PostalCode":"47900","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Legnano (MI","Latitude":"45.5983403","CountryDisplay":"Italy","Longitude":"8.9142485","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20025","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ljubljana","Latitude":"46.0569465","CountryDisplay":"Slovenia","Longitude":"14.5057515","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Volgograd","Latitude":"48.7757346","CountryDisplay":"Russia","Longitude":"44.5419165","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"400040","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orel","Latitude":"52.9831962","CountryDisplay":"Russia","Longitude":"36.0822205","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"302040","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Belgorod","Latitude":"50.5640417","CountryDisplay":"Russia","Longitude":"36.5567945","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"308036","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Graz","Latitude":"47.0703645","CountryDisplay":"Austria","Longitude":"15.4114059","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"A-8020","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 23:02:42","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"1","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"A retrospective, multi-centre observational study to evaluate disease management and adverse events in adult subjects with HIV-1 infection who were withdrawn from CNA106030 due to a positive HLA-B*5701 test result","org_study_id":"CNA108223","overall_contact":{"email":null,"last_name":"US GSK Clinical Trials Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"","primary_compl_date":null,"primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"03/01/2007 00:00:00","study_type":"observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"CNA108223"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}